Accendra Health (ACH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for May 15, 2025, to be held virtually at 9:00 a.m. EDT.
Shareholders of record as of March 19, 2025, are eligible to vote.
Proxy materials, including the 2025 Proxy Statement and 2024 Annual Report, are available online.
Voting can be completed electronically or by requesting paper materials.
Voting matters and shareholder proposals
Election of nine directors for one-year terms and until successors are elected.
Ratification of KPMG LLP as independent registered public accounting firm for 2025.
Advisory vote to approve named executive officer compensation.
Provision to transact other business as may properly come before the meeting.
Board of directors and corporate governance
Nine director nominees listed for election, each for a one-year term.
Latest events from Accendra Health
- 2026 guidance projects $2.55–$2.65B revenue, $335–$355M EBITDA, and strong cash flow.ACH
Q4 202519 Feb 2026 - $1.36B Rotech deal expands Patient Direct, targets $5B revenue, $50M synergies by year three.ACH
M&A Announcement3 Feb 2026 - Q2 revenue up 4–4.2% to $2.67–$2.7B; Rotech deal announced; 2024 outlook reaffirmed.ACH
Q2 20242 Feb 2026 - Q3 revenue up 5% to $2.7B, driven by Patient Direct and $198M debt reduction.ACH
Q3 202417 Jan 2026 - Proxy covers director elections, auditor ratification, say-on-pay, and strong ESG focus.ACH
Proxy Filing1 Dec 2025 - 2024 delivered higher revenue, major debt reduction, and a strong 2025 growth outlook.ACH
Q4 20241 Dec 2025 - Patient Direct led Q1 gains as guidance was reaffirmed and major deals and tariffs shaped outlook.ACH
Q1 202526 Nov 2025 - Q2 2025 saw revenue growth, margin gains, and a wider GAAP net loss on major one-time charges.ACH
Q2 202523 Nov 2025 - Divestiture enables focus on home-based care; Q3 2025 saw net loss but guidance reaffirmed.ACH
Q3 20253 Nov 2025